All posts by imreal

First Chicago Insurance Company Expands Its Public and Specialty Transportation Commercial Automobile Insurance to Include the State of New Jersey


News Image

FCIC offers customized packages for a variety of classes in the public transportation segment. Our extensive experience combined with our ability to create innovative solutions help us meet the needs of our insureds.

Developed and marketed by Warrior Insurance Network (WIN) and First Chicago Insurance Company(FCIC), the Public and Specialty Transportation Commercial Automobile Insurance Program is now available in New Jersey, as well as Illinois, Indiana, Louisiana (Limo only), Ohio, Pennsylvania, and Wisconsin. “With company history dating back to 1920, First Chicago Insurance Company (FCIC) was established to meet the unique needs of commercial auto businesses. Back then, business owners were companies that delivered ice to local businesses. Over a hundred years later, FCIC has evolved into a multi-line insurance carrier, now offering Personal & Commercial Auto Insurance and General Liability in response to the needs of the company’s customer base and independent producers. FCIC provides a quality commercial auto insurance program that offers competitive rates and first-class personalized claim service.”

“After thorough market analysis, FCIC’s Public and Specialty Transportation Commercial Automobile Insurance program was expanded to meet the commercial auto insurance needs of this niche market,” explained Mark Bissonette, Vice President, Commercial Lines Underwriting, FCIC.

“FCIC offers customized packages for a variety of classes in the public transportation segment, from large fleet operations to individual owner operators. Our extensive experience in public transportation insurance, combined with our ability to create innovative solutions help us meet the needs of our insureds,” Bissonette added.

FCIC’s Public and Specialty Transportation Commercial Automobile Insurance Program’s classification portfolio was expanded and now encompasses:

  • Taxi
  • Limousine
  • Stretch Limousine
  • Car Service
  • Paratransit/Non-Emergency Medical Transportation (NEMT)
  • Charter Bus/Limo Bus
  • Van Pool
  • Jitney
  • Airport Bus/ Airport Limo
  • Social Service Agency Auto

In New Jersey, FCIC’s Public and Specialty Transportation Commercial Automobile Insurance does limit offerings to vehicles seating 13 passengers or less. The product offers a variety of discounts, billing plans, coverages, and other unique features to meet the needs of the growing public transportation industry.

FCIC possesses the knowledge and expertise needed to provide appropriate commercial auto insurance coverage and can customize an insurance policy to suit a customer’s business needs. FCIC has a dedicated underwriting team that is powered by experienced insurance professionals, utilizing analytics to ensure proper pricing for qualifying accounts.

Bissonette concluded, “the Public and Specialty Transportation sector plays a vital role in today’s business landscape. Business owners choose FCIC because of our full range of commercial vehicle insurance products, great rates, and first-class service. FCIC’s team of dedicated insurance professionals can help you find the commercial auto insurance you’re looking for. FCIC’s Public and Specialty Transportation Commercial Automobile Insurance recognizes the unique risks of the transportation industry and has the right coverage solutions to meet the needs of the industry.”

For prompt service, please send all inquiries to the Commercial Department at commercialaccounts@firstchicagoinsurance.com or call 708-552-4400 ext. 4209.

About First Chicago Insurance Company and Warrior Insurance Network:

First Chicago Insurance Company (FCIC) is a member of the Warrior Insurance Network (WIN). FCIC, whose roots trace back to 1920, has evolved into a multi-line insurance carrier, now offering Personal & Commercial Auto and General Liability insurance in response to the needs of the company’s independent producers and customer base. In personal lines, FCIC has further responded to the changing exposures and needs of their independent producers by adding optional insurance coverages such as Contents Plus Renters, Roadside Assistance, and Transportation Network Coverage to enhance their personal lines auto offerings. FCIC currently offers insurance via independent agencies throughout Illinois, Indiana, Iowa, Kansas, Louisiana, Missouri, New Jersey, Ohio, Pennsylvania, Texas, and Wisconsin. First Chicago Insurance Company is headquartered at 6640 S. Cicero Avenue, Bedford Park, IL, 60638, 888-262-8864. http://www.FirstChicagoInsurance.com.

About Warrior Insurance Network

Warrior Insurance Network (WIN) entities include First Chicago Insurance Company, United Security Health and Casualty Insurance Company, Texas Ranger MGA and Lonestar MGA. WIN is a marketing organization servicing a select group of insurance carriers and independent insurance agents which offer a diverse array of personal and commercial auto insurance products. WIN member companies are admitted in the states of Arizona, Arkansas, Colorado, Georgia, Illinois, Indiana, Iowa, Kansas, Louisiana, Maryland, Missouri, Nebraska, Nevada, New Jersey, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas, Virginia, and Wisconsin. WIN is headquartered at 6640 S. Cicero Avenue, Bedford Park, IL, 60638, 844-281-1605 ext.4230. http://www.WarriorInsuranceNetwork.com

Share article on social media or email:

Unitek Joins Forces with Trusted Health to Expand Workforce Education


Unitek Learning is the parent company of several distinguished learning institutions: Unitek College, Unitek EMT, Eagle Gate College, Provo College, and Brookline College.

Trusted Health nurses can advance their careers through several programs offered by Unitek Learning schools.

Unitek Learning is thrilled to announce that it has joined forces with Trusted Health, the leading labor marketplace for healthcare professionals. Founded in 2017, Trusted Health matches nurses with a range of flexible jobs that meet their preferences and career goals. They also offer support from a dedicated Clinical Care Team as well as unmatched insight into compensation and contract details. Trusted Works is their flagship staffing platform that helps hospitals meet one of their single biggest challenges: ensuring that every shift gets filled in an environment where both demand for healthcare services and the cost of labor are increasing exponentially.

Now, Trusted Health nurses can advance their careers through several programs offered by Unitek Learning schools. These individuals will have the opportunity to enjoy a special tuition rate as well as other savings that can be applied to pathways like the Bachelor of Science in Nursing (BSN) degree, the RN-to-BSN completion program, the Master of Science in Nursing degree, and the Master’s Entry Program in Nursing.

“Our goal is to work with Trusted Health on workforce development. We understand that students don’t just want to land that dream job—they want that dream job to continue to evolve and grow with them,” said Janis Paulson, Chief Executive Officer at Unitek Learning. “With that in mind, we have educational pathways to help advance the workforce so they can take advantage of every opportunity they want today and down the road.”

“At Unitek, we are committed to education and workforce alignment so that the next generation can thrive,” said Karilyn Van Oosten, Vice President of Strategic Business Development at Unitek Learning. “We’re honored to join forces with Trusted Health and help transform the healthcare workforce. As a learning institution, we want to help professionals advance in their career and reach their professional potential. This is a step forward for Unitek as we continue to educate future healthcare professionals.”

Unitek Learning is the parent company of several distinguished learning institutions: Unitek College, Unitek EMT, Eagle Gate College, Provo College, and Brookline College. Unitek programs teach the clinical practices and theory used in the field today. Equipped with a multitude of sought-after skills, Unitek graduates are prepared to excel in many of the fastest-growing careers in healthcare and nursing.

To find out how to take advantage of all this partnership affords, call 888.382.8183 or contact us today.

Share article on social media or email:

1st Annual Quality Management vSummit on October 11-12, 2022


1st Annual Quality Management vSummit

Optimizing Your Quality Management Program to Be Both World Class and FDA-Compliant

A WCG FDAnews Virtual Summit

Tuesday, October 11 to Wednesday, October 12, 2022

https://wcg.swoogo.com/quality-managment-summit

If pharmaceutical and device manufacturers’ quality management systems (QMS) are not world class, they may be falling behind.

Alongside fulfilling patient and FDA expectations, a QMS can go beyond simple compliance to increase continual improvement and quality culture for powerful business benefits.

The 1st Annual Quality Management vSummit: Optimizing Your Quality Management Program to Be Both World Class and FDA-Compliant will empower attendees to develop a world-class QMS by implementing the essentials of quality management maturity (QMM) metrics, something the FDA’s Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Health (CDRH) advocate.

Rather than promoting feel-good language or wishful thinking, the vSummit will detail how to ensure pharmaceutical and device manufacturers’ quality culture is a high-powered functional tool. Sessions will demonstrate the importance of quality culture to standardize efficient behaviors via meaningful metrics.

Attendees will come away with the knowledge and know-how to create a world-class QMS:


  • What the FDA looks for in a QMS
  • How to ensure that continuous improvement initiatives address GMP and other regulatory requirements, including the FDA’s expectations resulting from the COVID-19 experience
  • How to ensure that a drug or device meets the quality expectation of consumers
  • The importance of creating quality milestones and incentives that are patient-focused and transparent to give a demonstrable advantage over competitors and credibility with the FDA
  • How to develop QMM metrics that go beyond mere numbers and actually measure quality
  • The importance of quality culture as a tool to standardize efficient behaviors via meaningful metrics
  • How to meet supply chain challenges and evaluate vendors to ensure quality service
  • How to optimize quality by ensuring data is accurate and determining the degree of risk that will lead to the management of quality, and will get manufacturers to the intersection where data integrity, risk management and quality management meet
  • How to establish a culture of quality throughout your organization

Compliance alone is no longer enough; pharmaceutical and device manufacturers must embrace continual improvement and quality culture. Develop and maintain a world-class QMS, and a world-class business, with the 1st Annual Quality Management vSummit.

Workshop Details

1st Annual Quality Management vSummit

Optimizing Your Quality Management Program to Be Both World Class and FDA-Compliant

A WCG FDAnews Virtual Summit

October 11 -12, 2022

https://wcg.swoogo.com/quality-managment-summit

Price:

Early Bird Price: Register by September 16, 2022 — $597

After September 16, 2022 — $697

Easy Ways to Register:

Online: https://wcg.swoogo.com/quality-managment-summit

By phone: 888.838.5578 or 703.538.7600

About WCG FDAnews:

WCG FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on WCG FDAnews’ newsletters, books, databases, webinars and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations. Learn more at fdanews.com.

Share article on social media or email:

Mercy Surgical Oncologist Dr. Debashish Bose Now Seeing Patients at Meritus Medical Center in Hagerstown, MD


Debashish Bose, M.D., PhD, FACS, serves as Medical Director of The Center for Hepatobiliary Disease at Mercy Medical Center as well as Associate Director of Surgical Oncology at Mercy in Baltimore, MD.

Debashish Bose, M.D., PhD, FACS, serves as Medical Director of The Center for Hepatobiliary Disease at Mercy Medical Center in Baltimore, MD.

“I am really very happy to be able to see patients at Meritus as part of the ongoing mission to bring Mercy quality care to patients throughout Maryland, and to make that care accessible by being closer to where our patients work and live.” — Debashish Bose, M.D., PhD, FACS

Debashish Bose, M.D., PhD, FACS, Medical Director of The Center for Hepatobiliary Disease at Mercy Medical Center, Mercy Health Services (MHS), as well as Associate Director of Surgical Oncology at Mercy, is now seeing patients at Meritus Medical Center, an acute care hospital located in Hagerstown, MD, and part of the Meritus Health system.

Dr. Bose will see patients on two days each month at the Robinwood Professional Center and will perform surgeries at Meritus Medical Center. He also cares for patients at Mercy Medical Center and sees patients in the Surgical Oncology Clinic in the Weinberg Cancer Center at Mercy.

Mercy Health Services and Meritus Medical Center (Hagerstown Hospital) have enjoyed a relationship that spans more than a decade to when Meritus first joined Mercy’s Gynecologic Oncology Collaborative, a statewide network providing world class gynecologic cancer care throughout the region.

“I am really very happy to be able to see patients at Meritus as part of the ongoing mission to bring Mercy quality care to patients throughout Maryland, and to make that care accessible by being closer to where our patients work and live,” Dr. Bose said.

Dr. Bose is an expert at the treatment of diseases of the pancreas, liver, biliary tract, and complex upper gastrointestinal surgery. Throughout his career, Dr. Bose has sought to innovate, developing expertise in minimally invasive and robotic surgery, and initiating a cutting edge program in the use of Nanoknife in the treatment of cancer. Nanoknife is a tool used to ablate tumors located near critical structures that would otherwise not be amenable to surgical removal.

Dr. Bose has served as Principle Investigator in studies related to the treatment and detection of pancreatic cancer. Dr. Bose obtained an MD/PhD degree at the University of Maryland School of Medicine. After his residency at the Johns Hopkins Hospital, Dr. Bose pursued a clinical fellowship as well as postdoctoral training at the University of Texas MD Anderson Cancer Center, the foremost cancer center in the United States. While there, Dr. Bose was the recipient of the Ruth L. Kirschstein National Research Service Award.

Located at 11116 Medical Campus Road in Hagerstown, Meritus Medical Center has 300 beds and provides patients with a special care nursery, a level III trauma program, a primary stroke center, a wound center, a cardiac diagnostic laboratory, and other clinical services.

Founded in 1874 in downtown Baltimore by the Sisters of Mercy, Mercy Medical Center is a 183-licensed bed acute care university-affiliated teaching hospital. Mercy has been recognized as a top Maryland hospital by U.S. News & World Report; a Top 100 hospital for Women’s Health & Orthopedics by Healthgrades; and is recognized by the American Nurses Credentialing Center as a Magnet Hospital. Mercy Medical Center is part of Mercy Health Services (MHS), the parent of Mercy’s primary care and specialty care physician enterprise, known as Mercy Personal Physicians, which employs more than 200 providers with locations in Baltimore, Lutherville, Overlea, Glen Burnie, Columbia and Reisterstown. For more information about Mercy, visit http://www.mdmercy.com, MDMercyMedia on Facebook, Twitter, or call 1-800-MD-Mercy.

Share article on social media or email:

AxioMed LLC Submits Final Module III to the FDA Becoming the First and Only Lumbar Viscoelastic Total Disc Replacement Company to Complete a USA IDE Clinical Trial


KICVentures Group portfolio company AxioMed has the only Lumbar Viscoelastic Disc Replacement Medical Device in the USA with global clinical use since 2008 and no device failure

“We are preparing to begin training surgeons early 2023 in anticipation of FDA approval,“ said Professor Dr. Kingsley R Chin, a board-certified orthopedic spine surgeon.

AxioMed LLC shows its determination to press forward on its FDA submission of Module III documents needed to get FDA approval to market its lumbar viscoelastic disc replacement in the USA.

“We were dedicated and determined to continue answering questions from the FDA on the Module I and II submissions while completing the clinical data analyses and documentation required to submit the final Module III package by August 2022. Now, the last step remaining is an FDA site inspection of the cleanroom manufacturing facilities to complete the full submission process, ”says Vito Lore VP of Innovations.

“Lumbar disc replacement is a disruptive enabling technology with a growing global market valued at an estimated $1.8 Billion by 2027,” says Chief Financial Officer, Aditya Humad.

https://www.coherentmarketinsights.com/press-release/lumbar-disc-replacement-device-market-3324

AxioMed stands as the only viscoelastic disc replacement to ever complete a US IDE Clinical study. The clinical data is strong with greater than five year followup data showing no reported device related failures, no revisions and rare cases of heterotopic bone formation. Outside the USA, the cervical and lumbar discs have been used clinically in Australia, Europe and the Caribbean.

“We are preparing to begin training surgeons early 2023 in anticipation of FDA approval,“ said Professor Dr. Kingsley R Chin, a board-certified orthopedic spine surgeon.

“There is growing demand among spine surgeons for disc replacements to substitute for spinal fusions,” said Dr. Erik Spayde, a board-certified orthopedic spine surgeon and prolific disc replacement surgeon.

The AxioMed viscoelastic disc replacement is widely anticipated in the USA and internationally as a major advance in disc replacement technology. The current ‘ball and socket’ designs on the market are seeing favorable results and growing adoption over traditional spinal fusion. However, there is still need for improvement in disc technology and the consensus is to move to viscoelastic elastomeric disc replacement solutions with natural spine motion. AxioMed’s Module III lumbar clinical data shows no production of wear debris, and minimal formation of heterotopic bone in patients. In contrast, ‘ball and socket’ articulating disc replacements have been plagued by heterotopic bone formation and by the production of microscopic wear debris which causes bone osteolysis as we saw in hip and knee joint replacements in the early years. Currently, only two lumbar disc replacements are being commercialized in the USA. More and more health insurance companies are reimbursing lumbar disc replacement and this trend will likely accelerate with the drive to do more surgeries in outpatient ambulatory surgery centers where cost is lower and outcomes are better with fewer complications.

About AxioMed

AxioMed was founded in 2001 by surgeons at Cleveland Clinic and engineers who previously worked with Dr. Art Steffee and Acroflex viscoelastic disc replacement. The current AxioMed disc comprises of a proprietary silica-based viscoelastic material proven in extensive biomedical/biocompatible testing to mimic the human disc in all planes and 50+ years of longevity testing. The viscoelastic material is radiolucent and thus X-ray and MRI compatible. Over 800 discs have been implanted worldwide with zero failures or revisions. It is the only viscoelastic lumbar disc to complete a USA IDE clinical study with 10+ years of follow-up.

http://www.AxioMed.com

About KICVentures Group

Our founders have been investing in spine surgery 2000 makes us the most experienced healthcare investment holding company with the largest portfolio of medical device technologies focused on solutions for less invasive outpatient spine surgery. Our investment strategy is to acquire or invent disruptive technologies using our own capital or partner with private individual investors. This allows us the freedom to make quick and nimble decisions such as when we acquired AxioMed Viscoelastic Disc Technologies while other companies invested in spinal fusion.

http://www.KICVenturesGroup.com

Share article on social media or email:

Quantiphi Earns Frost & Sullivan’s North America Competitive Strategy Leadership Award in Artificial Intelligence Services for the Healthcare Industry


“Our leading-edge AI solutions and capabilities have allowed us to help healthcare ecosystem clients including providers, payers, life sciences and public sector organizations to realize the strategic benefits of their digital transformation initiatives .” – Bruno Nardone, Quantiphi

Quantiphi, an AI-first digital engineering company, has been awarded the Frost & Sullivan’s North America Competitive Strategy Leadership Award in AI Services for the Healthcare Industry. Frost & Sullivan recognizes companies that are at the forefront of innovation and growth in their respective industries, and consistently develop growth strategies to solve challenges and create new opportunities effectively.

The award comes to Quantiphi after qualifying through a rigorous analytical process established by Frost & Sullivan that evaluates best practices criteria across strategy, innovation, and customer impact. This award further showcases Quantiphi’s depth of expertise acknowledged in 2021 when Frost & Sullivan recognized the organization for best practices in AI services in the public sector. By strategically broadening its offering portfolios, Quantiphi has successfully addressed the compounding challenges of disruptive technologies, value chain compression, industry convergence, and changing business models within the healthcare industry. This award additionally celebrates the efforts of employees, customers, partners, and investors that support Quantiphi’s growth.

“We’re delighted to receive this award that recognizes our commitment to build state-of-the-art AI solutions to overcome the unique data and infrastructure challenges faced by the healthcare industry,” said Bruno Nardone, Global Leader, Healthcare and Life Sciences at Quantiphi. “Our leading-edge AI solutions and capabilities have allowed us to help healthcare ecosystem clients including providers, payers, life sciences and public sector organizations to realize the strategic benefits of their digital transformation initiatives .”

With the healthcare sector experiencing complex data and infrastructure challenges that make it difficult to navigate siloed and disparate data sets, healthcare stakeholders are struggling to formalize a clear roadmap to adopt digital strategies while maintaining data integrity and regulatory compliance. Quantiphi is committed to continuing investment in this target market segment and delivering innovative solutions to meet the scientific, business, and clinical needs unique to healthcare stakeholders. This commitment will include optimizing the use of existing robust partner technologies to address known focal points or developing new AI/ML offerings aligned with emerging challenges.

“Frost & Sullivan has selected Quantiphi for this award based on continuous innovation that supports and improves existing healthcare technologies,” said Pavel Zhebrouski, Research Analyst. “Quantiphi stands out with its expertise in streamlining and accelerating solutions’ adoption, providing strategic advice, and ensuring solutions and services are HIPAA-, GDPR-, and GxP-compliant.”

Quantiphi’s strong partnerships with market leaders such as Google, AWS, and Nvidia have enhanced its capabilities to build industry-leading solutions. Quantiphi was recently named the launch partner for Google Cloud’s Healthcare Data Engine, an intelligent end-to-end solution facilitating a real-time, holistic view of patient records, easily accessible by healthcare leaders, researchers, and clinicians in a secure, compliant, and scalable cloud environment. It allows for easy and standardized data exchange among different applications and solutions within an organization. By leveraging the Google Cloud Platform and other partner channels, Quantiphi has the freedom to innovate solutions in a real-world customer environment. Healthcare Data Engine is HIPAA and other healthcare safety and data privacy regulations compliant, and enables a secure environment to build data-driven clinical analytics solutions.

Frost & Sullivan cited many of Quantiphi’s success stories and achievements in its report, strengthening Quantiphi’s position as a Competitive Strategy Leader in the AI services in the healthcare industry. Frost & Sullivan acknowledges Quantiphi’s focused approach to AI-enabled digital transformation in the healthcare sector, helping clients outpace their competitors. Quantiphi has consistently developed strategies with customers in mind, which has helped it secure its position as a trusted partner and market leader.

About Quantiphi

Quantiphi is an award-winning AI-first digital engineering company driven by the desire to reimagine and realize transformational opportunities at the heart of the business. Quantiphi solves the toughest and complex business problems by combining deep industry experience, disciplined cloud, data-engineering practices, and cutting-edge artificial intelligence research to achieve quantifiable business impact at unprecedented speed. We are passionate about our customers and obsessed with problem-solving to make products smarter, customer experiences frictionless, processes autonomous and businesses safer by detecting risks, threats, and anomalies. Together with partners and customers, we embark on a data and AI-led transformation journey that delivers impactful and measurable results.

For more on Quantiphi’s capabilities, visit http://www.quantiphi.com

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Share article on social media or email:

Xenia Kovacs joins growing ECG Core Lab provider, HeartcoR Solutions, as associate director of clinical project management


Courtesy of HeartcoR Solutions.

The HeartcoR team has demonstrated a commitment to thoughtful collaboration and using the most advanced technology to ensure the safe, efficient, accurate, and timely completion of early- and late-stage ECG safety trials, and I am excited to be part of the company’s future growth.

HeartcoR Solutions, a leading ECG Core Lab provider that delivers ‘round the clock clinical research for cardiac safety studies to pharmaceutical, medical device, and CROs worldwide, announced today that Xenia Kovacs has joined the organization as associate director of project management.

Kovacs has more than 25 years of experience managing scientific clinical studies at premier healthcare and life sciences organizations. In her new role, she will provide leadership to HeartcoR’s project teams, while overseeing project management recruitment to accommodate an increase in the number and size of clinical trials HeartcoR is managing.

“Xenia’s demonstrated success managing clinical trial teams and programs will be critical as we continue to expand our operations and extend the reach of our services,” said John Icardi, president and COO, HeartcoR Solutions. “We are thrilled to add Xenia’s expertise to our dedicated team of clinical project managers who work tirelessly to support the needs of study sponsors and participants.”

Prior to joining HeartcoR, Kovacs served in senior clinical project management roles for Abbott Molecular, Abbott/AbbVie, and Pfizer. She earned a Bachelor of Science degree from Nagy Lajos College in Pecs, Hungary, and completed legal training at the University of Pecs School of Law. Kovacs has co-authored several scientific journal articles, and has been recognized for scientific excellence from leading neuroscience and pharmaceutical organizations.

“The HeartcoR team has demonstrated a commitment to thoughtful collaboration and using the most advanced technology to ensure the safe, efficient, accurate, and timely completion of early- and late-stage ECG safety trials, and I am excited to be part of the company’s future growth,” said Kovacs.

To learn more about HeartcoR Solutions, visit http://www.HeartcoRSolutions.com.

###

About HeartcoR Solutions

Headquartered in Schaumburg, IL, HeartcoR Solutions LLC. is a leading-edge ECG Core Lab providing 24/7 research and clinical trial management services to pharma, medical device and biotech companies worldwide. HeartcoR delivers non-invasive cardiovascular safety and efficacy services that enhance data capture, review and management in clinical research. Learn more at http://www.heartcorsolutions.com. Follow on LinkedIn, Twitter and YouTube.

Share article on social media or email:

Spot Pet Insurance Partners with Cameo to Provide More Videos of Pet-Loving Celebs Who Share Their Stories and Experiences as Pet Moms and Dads


Spot Pet Insurance is officially expanding their start-studded roster of celebrity brand advocates through its partnership with Cameo for Business. The legendary Paula Abdul, Hannah Brown, Tom Felton, and Bethenny Frankel have all made Business Cameo videos with Spot Pet Insurance. These celebrities and others have fallen in love with Spot Pet Insurance because of the way they treat pets just like family. Through Cameo, these celeb pet parents will be able to share their experiences with everyone and anyone, as they tell stories about their own furry-little-friends.

Not only will these stars share heart-warming stories about their pets, but they’ll also spend time reflecting on the impact and role that their pets have had in their lives. Pets are often welcomed into the family as an equal member, and in turn, need just as much love, protection, and support. Understanding that even house-hold name celebrities seek out help to support the lives and health of their pets, can encourage everyday pet owners to learn more about doing the same. Additionally, the campaign will serve to continue building the reputation of Spot Pet Insurance as a trustworthy leader in the field of pet insurance.

Cameo for Business and Spot Pet Insurance launched the original A-list celebrity-powered digital marketing campaign in April and have already seen incredible early success metrics including a 400% increase in click-through-rates and 30% lower customer acquisition cost compared to previous campaigns. Cameo for Business has been leveraging its expertise and data insights to help Spot develop the creative concepts, select talent, and manage the day-to-day of the campaign with their growth marketing partner, SWIDIA. Together they are launching the expanded campaign to continue bringing awareness about the importance of pet insurance to celebrities and everyday pet parents.

“We’re excited to continue helping Spot Pet Insurance lower acquisition costs and increase click through rates,” said Cameo VP of Growth, Marty Pesis. “This full funnel campaign has further validated the impact of Cameo for Business and the power of celebrity-driven content. We can’t wait to watch this new iteration of the campaign build on past success and drive even stronger results.”

###

About Spot Pet Services, LLC: Spot Pet Services, LLC is an insurance producer founded in West Palm Beach, Fl, that offers products nationwide. Spot offers plan options that include Accident-Only and Accident & Illness pet insurance. Spot provides insurance plan options, communications, and employees that support humans in forming the best relationship with their pets over a long, healthy life together. Pre-existing conditions are not covered. Waiting periods, annual deductible, co-insurance, benefit limits, and exclusions may apply. For all terms and conditions visit spotpetins.com/sample-policy. Products, schedules, discounts, and rates may vary and are subject to change. More information is available at checkout. Insurance plans are underwritten by United States Fire Insurance Company (NAIC #21113. Morristown, NJ). Insurance plans are marketed and produced by Spot Insurance Services, LLC. (NPN # 19246386).

About Cameo

Cameo is the leading marketplace connecting fans and brands directly with tens of thousands of pop culture personalities in the form of personalized video messages, engaging fan experiences, and marketing and events partnerships. Founded in March 2017 by Steven Galanis, Devon Townsend, and Martin Blencowe, Cameo’s mission is to create the most personalized and authentic fan experiences on Earth.

In just over five years, Cameo has fulfilled more than 4 million magical moments ranging from birthday and good luck messages to prom invitations, marriage proposals, and direct fan interactions. Throughout its history, Cameos have been delivered in 215 countries and on every continent in the world.

Share article on social media or email:

Sub-lobar Surgery for Peripheral Non-small Cell Lung Cancer non-inferior to Lobectomy


News Image

“The results of this trial show that for certain patients, sub-lobar resection is non-inferior to lobectomy.” — N.K. Altorki, MD, from Weill Cornell Medicine-New York Presbyterian Hospital in New York City.

A large international study of patients with non-small cell lung cancer tumors that are two centimeters or less found that sub lobar surgery was non-inferior to lobectomy, according to results presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

In sub-lobar resection, the surgeon removes only the tumor and a small portion of the lung compared to a lobectomy where an entire portion of the lung is removed. The increased detection of small-sized peripheral non-small cell lung cancer has renewed interest in sub-lobar resection in-lieu of lobectomy, according to N.K. Altorki, MD, from Weill Cornell Medicine-New York Presbyterian Hospital in New York City.

Dr. Altorki and his research colleagues conducted CALGB140503 (Alliance), a multicenter international non-inferiority phase III trial in which NSCLC patients clinically staged as T1aN0 ≤ 2 cm were randomly assigned to lobar or sub-lobar resection. Non-inferiority trials seek to determine if an experimental therapy is not worse than standard of care or the comparator therapy. The primary endpoint is disease-free survival and secondary endpoints included overall survival and the difference in pulmonary functions at six months postoperatively between arms.

The trial enrolled 1,080 patients with clinical stage IA NSCLC between June 2007 and March 2017. To be eligible for the study, patients had to have pathologically confirmed NSCLC and node-negative disease at level 10 and up to two mediastinal stations prior to randomization. Of the 1,080 patients enrolled, 697 patients were intraoperatively randomly assigned to either lobar (357 patients) or sub-lobar (340 patients) resection. Basic demographic and clinical characteristics were balanced between the two arms of the trial and minimally invasive approaches were utilized for 80% of all resections

Dr. Altorki and researchers at participating sites followed patients for seven years and determined the non-inferiority significance boundary had not been crossed. For disease-free survival, the primary endpoint of the trial, the stratified hazard ratio (HR) was 0.999 (95%CI,0.784 – 1.272, 90% CI, 0.816 – 1.224). For overall survival the stratified HR was 0.930 (95% CI, 0.695 – 1.243, 90% CI, 0.728 – 1.187). In the sub-lobar arm and the lobectomy arm the five-year disease-free survival rate was 63.9% (95% CI, 58.7-69.5), and 64.3% (95% CI,59.2-69.8), respectively.

Thirty- and 90-day mortality were 1.1% and 1.7% after lobar resection and 0.6% and 1.2% after sub-lobar resection.

The results of this large North American/international randomized trial show that for patients with peripheral NSCLC 2 cm or less in size who have pathologically confirmed node-negative disease in major hilar and mediastinal lymph nodes, sub-lobar resection is non-inferior to lobectomy.

About the WCLC:

The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2022.iaslc.org/

Share article on social media or email:

Tatnuck Park at Worcester Senior Programs Recognized As Being the Best in the Commonwealth


News Image

The Innovative Programs Offered at Tatnuck Park Include a Regular Drum Circle

“Ellen and our programming team are constantly thinking outside the box to ensure that every one of our residents is happy and doing what they love.” -Jennifer LaCroix, executive director, Tatnuck Park

Throughout its over 23-year history, Tatnuck Park at Worcester, a Benchmark assisted living and Mind & Memory Care community, has been known for its quality care and experiences. Last week, their commitment to being the best was again validated when it was awarded the Massachusetts Assisted Living Association (Mass-ALA) 2022 Excellence Award for Program Innovation.

Tatnuck Park’s programming director, Ellen Meagher, was recognized for creating unique, personalized programs that are not only fun and engaging for residents, but connect the entire community. Drum circle experiences, in particular, which feature movement to music, engage residents physically, mentally, emotionally and spiritually and strengthen connections between residents and associates. Also, intergenerational programs with Worcester State University occupational therapy students that inspire and enrich.

Meagher brings over 15 years of senior life enrichment experience to the assisted living community. She also holds a Master’s in leisure studies from Boston University and a Bachelor’s in therapeutic recreation from Springfield College.

“The measure of any high-quality assisted living community is its ability to really engage its residents in programs that they enjoy,” said Jennifer LaCroix, executive director of Tatnuck Park. “Ellen and our programming team are constantly thinking outside the box to ensure that every one of our residents is happy and doing what they love. I feel so honored to have our team recognized by our Massachusetts peers.”

Since its inception in 1999, Tatnuck Park has frequently been recognized for its care and programs. Most recently, it was only three communities in all of Central Massachusetts to be selected as a U.S. News 2022-2023 Best Assisted Living community.

Tatnuck Park at Worcester offers traditional senior assisted living and independent assisted living for those who would benefit from a safer, engaging environment, chef-prepared meals, supportive living services, transportation and assistance with daily activities, such as getting dressed and medication management. Residents benefit from partnerships with nearby university students for healthcare and social engagement. They also enjoy connecting over programs and amenities offered in many common spaces, including a demonstration kitchen, recreation room, library, hair salon and spa, sunroom, private dining room and outdoor courtyards with walking paths.

Tatnuck Park also offers an award-winning Mind & Memory Care program featuring carefully created living environments and unique opportunities for those with Alzheimer’s and dementia to find joy in each new day. Memory care assisted living residents are supported by 24/7 care providers who have been hired for heart and educated in memory loss, communication and empathy. Neighborhoods provide the comforts of home and have unique features that help those with memory impairment stay connected to who and what matters most to them. Thoughtful touches, visual cues and purposeful amenities further promote familiarity and wellness.

For more information, about Tatnuck Park at Worcester, click here.

# # #

About Benchmark Senior Living

Benchmark is New England’s largest senior living provider with 64 independent living, assisted living, memory care and continuing care communities and over 5,000 dedicated associates providing compassionate care and outstanding experiences throughout the Northeast. The Waltham, Mass.-based company was founded over 25 years ago by Tom Grape with the purpose of Transforming Lives Through Human Connection. Since then, Benchmark has continued to set the industry standard, having won over a hundred local, regional and national awards for its care, programs and as a top workplace. Benchmark has been named one of the Top Places to Work for 14 straight years in The Boston Globe’s annual employee-based survey and received repeated recognition in FORTUNE’s Best Workplaces for Aging Services list. For more information, visit BenchmarkSeniorLiving.com.

Share article on social media or email: